Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Royalty Pharma PLC (RPRX) had Revenue of $621.99M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$621.99M
Net Income	$214.21M
Cost of Goods Sold	--
Gross Profit	$621.99M
Operating Expenses	$233.61M
Operating Income	$388.38M
Non-Operating Income/Expense	$-32.47M
Pre-Tax Income	$355.91M
Normalized Pre-Tax Income	$328.83M
Income after Taxes	$355.91M
Income from Continuous Operations	$355.91M
Consolidated Net Income/Loss	$355.91M
Normalized Income after Taxes	$328.83M
EBIT	$388.38M
EBITDA	$397.12M
Weighted-Average Shares Outstanding (Basic)	429.80M
Weighted-Average Shares Outstanding (Diluted)	564.46M
Earnings per Share (EPS) (Basic)	$0.50
Earnings per Share (EPS) (Diluted)	$0.49
Balance Sheet Financials
Current Assets	$1.53B
Property, Plant, and Equipment	$16.21B
Long-Term Assets	$18.09B
Total Assets	$19.62B
Current Liabilities	$636.21M
Long-Term Debt	$8.57B
Long-Term Liabilities	$9.27B
Total Liabilities	$9.91B
Common Equity	$9.71B
Tangible Shareholders Equity	$8.79B
Shareholders Equity	$9.71B
Common Shares Outstanding	988.63M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$2.49B
Cash Flow from Investing Activities	$-1.61B
Cash Flow from Financial Activities	$-1.19B
Beginning Cash	$929.03M
End Cash	$618.70M
Increase/Decrease in Cash	$-310.33M
Stock-Based Compensation	$289.89M
Common Stock Dividends Paid	$-900.63M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.40
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.47
Debt to Equity Ratio	0.92
Gross Margin	100.00%
Operating Margin	62.44%
EBIT Margin	62.44%
EBITDA Margin	--
Pre-Tax Profit Margin	57.22%
Profit Margin	34.44%
Free Cash Flow	$2.49B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.03
Inventory Turnover	--
Receiveable Turnover	21.22
Days Sales in Receivables	4.24
Return on Equity	3.66%
Return on Tangible Equity	4.05%
Return on Assets	1.81%
Return on Investments	1.95%
Book Value Per Share	$9.83
Free Cash Flow per Share	$4.41
Operating Cash Flow per Share	$4.41

Data from Zacks Investment Research, Inc.